share_log

Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs

Tharimmune Has Entered Into A Securities Purchase Agreement To Raise ~$2.02M Through A Private Placement, To Advance Development Programs

Tharimmune已經簽署了一項證券購買協議,通過定向增發籌集約202萬美元,以推進開發項目
Benzinga ·  12/07 05:19

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.

納斯達克上市公司Tharimmune, Inc.(納斯達克股票代碼:THAR)("Tharimmune"或"公司"),一家臨床階段生物技術公司,致力於在免疫學和炎症領域開拓治療方法,今日宣佈已簽署證券購買協議,通過定向增發募集約202萬美元的募資。

The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.

該協議包括髮行961,446股普通股(或普通股等效證券)和購買權證,可購買最多額外480,723股普通股。每股(或普通股等效證券)定價爲2.10美元,並附帶一項認股權證。認股權證行權價爲每股2.031美元,六個月後成爲行權期,並在發行日後五年半到期。預計本交易將於2024年12月9日左右結束,須符合慣例的成交條件。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論